Purpose The PI3K/Akt/mTOR pathway is activated in the majority of pancreatic cancers, and
inhibition of this pathway has antitumor effects in preclinical studies. We performed a multi …

Mammalian target of rapamycin (mTOR) is a central controller of cell growth, proliferation,
metabolism and angiogenesis. mTOR signaling is often dysregulated in various human …

The mammalian target of rapamycin (mTOR) is an intracellular serine/threonine protein
kinase positioned at a central point in a variety of cellular signaling cascades. The …

Building on years of basic scientific discovery, recent advances in the fields of cancer
genetics and medicinal chemistry are now converging to revolutionize the treatment of …

Purpose To evaluate the safety and efficacy of oral everolimus, a mammalian target of
rapamycin (mTOR) inhibitor, in two different schedules in minimally pretreated patients with …

ABSTRACT PI3K/AKT/mTOR signaling pathway is one of the key dysregulated pathways in
different tumor types, including colorectal cancer (CRC). Activation of this pathway is shown …

Purpose Buparlisib, an oral reversible inhibitor of all class I phosphoinositide-3-kinases, has
shown antitumoral activity against estrogen receptor (ER)-positive breast cancer cell lines …

The mammalian target of rapamycin (mTOR) has emerged as a potential target for drug
development, particularly due to the fact that it plays such a crucial role in cancer biology. In …

The discovery of 2 (GDC-0980), a class I PI3K and mTOR kinase inhibitor for oncology
indications, is described. mTOR inhibition was added to the class I PI3K inhibitor 1 (GDC …

Everolimus, an orally administered rapamycin analog, has recently been approved by the
US Food and Drug Administration for treatment of renal cell carcinoma (RCC) refractory to …